Navigation Links
Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
Date:1/6/2009

Lead candidate on track for IND submission first half of 2009.

SAN DIEGO, Jan. 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced AM211, Amira's internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway, is on target for submission of an IND to the U.S. Food and Drug Administration (FDA) by mid-2009 following the successful completion of Good Laboratory Practices (GLP) toxicity studies.

AM211 is an oral, selective antagonist of the receptor DP2 (also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes). DP2 is a high affinity receptor for prostaglandin (PG) D2 and, in humans, is implicated in Th2-dependent allergic inflammation. Recent studies have shown that a DP2 antagonist has the potential to be an oral treatment for asthma, Chronic Obstructive Pulmonary Disease (COPD) and allergic rhinitis.

"Our pre-clinical studies demonstrate that a low dose of AM211 is effective in several inflammatory/allergic models," said Peppi Prasit, PhD, Chief Scientific Officer, Amira. "Based on the pharmacokinetics and pharmacodynamics in preclinical models and its safety profile, we believe that AM211 has the potential to be an exciting next generation, once a day oral medication for respiratory diseases including COPD. In addition, we have a structurally distinct backup compound, AM461, about to enter GLP toxicity studies."

"Amira is establishing a track record of rapid and efficient discovery and early drug development. For the second time in as many programs, Amira is on track to enter human studies within two years from program start," said Bob Baltera, Amira's Chief Executive Officer. "These are exciting times at Amira as our team continues to demonstrate world-class capabilities in drug discovery and development."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the phospholipid pathways. Amira has a strategic partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
2. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Amira Pharmaceuticals Appoints First Vice President of Development
5. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
6. American Asthma Foundation Announces Breakthrough Discovery
7. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
8. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
9. DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
10. FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
11. B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
Breaking Medicine Technology: